Thais Tunes Santos

Thais Tunes Santos

Auto-generated profile, based on publicly available information

Thais Tunes Santos

Institute of Biological Sciences

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Frédéric FrézardFrédéric Frézard
Frédéric Frézard
MAMarta Gontijo Aguiar
Marta Gontijo Aguiar
LFLucas Ferreira
Lucas Ferreira
GRGuilherme S. Ramos
Guilherme S. Ramos
TSThais T. Santos
Thais T. Santos
HMHelane L. O. De Morais
Helane L. O. De Morais
The liposomal amphotericin B (AmB) formulation, AmBisome®, still represents the best therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy depends on the patient’s immunological status, the clinical manifestation and the endemic region. Moreover, the need for parenteral administration, its side effects and high cost significantly limit its use in developing countries. This review reports the progress achieved thus far toward the understanding of the mechanism responsible for the reduced toxicity of liposomal AmB formulations and the factors that influence their efficacy against leishmaniasis. It also presents the recent advances in the development of more effective liposomal AmB formulations, including topical and oral liposome formulations. The critical role of the AmB aggregation state and release rate in the reduction of drug toxicity and in the drug efficacy by non-invasive routes is emphasized. This paper is expected to guide future research and development of innovative liposomal formulations of AmB.

1 August 2022 in Nanomedicine
Verified
Journal Article
Closed access
IMIzabela Mansur-Alves
Izabela Mansur-Alves
BLBrenda Lorrayne Furtado Lima
Brenda Lorrayne Furtado Lima
TSThais Tunes Santos
Thais Tunes Santos
NANaialy F Araújo
Naialy F Araújo
Frédéric FrézardFrédéric Frézard
Frédéric Frézard
MAMarta Gontijo Aguiar
Marta Gontijo Aguiar
Aim: Amphotericin B (AmB) is an antileishmanial drug with high toxicity; however, this drawback might overcome by decreasing the AmB self-aggregation state. This work aimed at evaluating the influe... Graphical abstract

7 October 2025 in ACS Omega
Verified
Journal Article
Open access
TSThais T. Santos
Thais T. Santos
Eduardo Burgarelli LagesEduardo Burgarelli Lages
Eduardo Burgarelli Lages
TRTiago N. Q. Ricotta
Tiago N. Q. Ricotta
LOLeandro G. de Oliveira
Leandro G. de Oliveira
GRGuilherme S. Ramos
Guilherme S. Ramos
Frédéric FrézardFrédéric Frézard
Frédéric Frézard
Leishmaniasis is a neglected tropical disease that mainly affects socially vulnerable populations. It is caused by various Leishmania species, and manifests primarily as cutaneous (CL) or visceral leishmaniasis (VL). AmBisome, a commercial formulation of amphotericin B (AmB) with conventional liposomes, is the most effective for VL treatment, but its efficacy is limited in some CL cases and immunocompromised patients. This work evaluated a new PEGylated liposomal formulation (LAmB-RA) coencapsulating AmB and retinoic acid (RA), as an immunomodulator, for CL treatment. LAmB-RA displayed a mean size of 125 nm, a polydispersity index <0.2, and high encapsulation efficiencies for AmB (97.1%) and RA (94.7%). Although SAXS analysis indicates that RA did not induce major structural rearrangements in the liposomal bilayer, comparison of circular dichroism spectra between LAmB-RA and the liposomal AmB formulation without RA (LAmB) revealed slightly different aggregated states of AmB. In addition, LAmB-RA showed a significantly reduced hemolytic activity, compared to LAmB. Pharmacokinetic analysis of the PEGylated formulations showed higher C max and prolonged plasma exposure of AmB compared to AmBisome. In Leishmania major-infected mice, LAmB-RA significantly reduced lesion size and parasite burden (99%) versus untreated control. In the Leishmania amazonensis model, it markedly inhibited lesion progression and was the only treatment to significantly reduce parasite load in the spleen (by 60%). Additionally, LAmB-RA promoted an increase in the IFN-γ/IL-10 ratio in antigen-stimulated splenocytes compared to LAmB, indicating a Th1-skewed immune response. These results support LAmB-RA as a promising therapeutic strategy for CL, combining prolonged circulation and enhanced efficacy.

31 January 2024 in Nanomedicine
Verified
Journal Article
Closed access
GBGabriel Borges
Gabriel Borges
TSThais Tunes Santos
Thais Tunes Santos
CPCristiane Monteiro Pinto
Cristiane Monteiro Pinto
Frédéric FrézardFrédéric Frézard
Frédéric Frézard
VBVerônica Freitas Blanco
Verônica Freitas Blanco
GGGisele Assis Castro Goulart
Gisele Assis Castro Goulart
Aim: To develop nanoemulsions (NEs) loading amphotericin B (AmB) and to evaluate the influence of different excipients on the stability and the supramolecular organization, retention and toxicity o... Graphical abstract Disteaoryl phosphatidylglycerol and dioleoyl phosphatidylglycerol form a hydrophobic ion pair with amphotericin B in nanoemulsions, enhancing drug retention after dispersion and ...

9 August 2024 in Nanomedicine
Verified
Journal Article
Closed access
VCValéria Moreira da Costa
Valéria Moreira da Costa
TSThais Tunes Santos
Thais Tunes Santos
NPNatalha Pinto
Natalha Pinto
Guilherme CarneiroGuilherme Carneiro
Guilherme Carneiro
Frédéric FrézardFrédéric Frézard
Frédéric Frézard
GBGabriel Borges
Gabriel Borges

6 August 2026 in Acta Tropica
Verified
Journal Article
Closed access
IMIsabela Cristina Soares Martins
Isabela Cristina Soares Martins
TSThaís Tunes Santos
Thaís Tunes Santos
CQCelso Martins Queiroz-Junior
Celso Martins Queiroz-Junior
ECEDUARDO COELHO
EDUARDO COELHO
MCMariza Gabriela Faleiro de Moura Lodi Cruz
Mariza Gabriela Faleiro de Moura Lodi Cruz
RORenata Oliveira
Renata Oliveira